| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival with ipilimumab in patients with metastatic melanoma.
|
N Engl J Med
|
2010
|
67.34
|
|
2
|
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
|
Lancet Oncol
|
2009
|
8.68
|
|
3
|
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
|
J Clin Oncol
|
2008
|
3.82
|
|
4
|
KIT as a therapeutic target in metastatic melanoma.
|
JAMA
|
2011
|
3.49
|
|
5
|
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
|
Br J Haematol
|
2005
|
2.55
|
|
6
|
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
|
Pigment Cell Melanoma Res
|
2008
|
1.98
|
|
7
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Nat Rev Clin Oncol
|
2013
|
1.46
|
|
8
|
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
|
Sci Transl Med
|
2014
|
1.30
|
|
9
|
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
|
Clin Cancer Res
|
2011
|
1.28
|
|
10
|
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
|
Clin Cancer Res
|
2010
|
1.19
|
|
11
|
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
|
Br J Haematol
|
2006
|
1.13
|
|
12
|
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
|
Br J Haematol
|
2009
|
1.11
|
|
13
|
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
|
J Clin Oncol
|
2009
|
1.01
|
|
14
|
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.
|
Melanoma Res
|
2005
|
0.90
|
|
15
|
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.
|
Invest New Drugs
|
2006
|
0.83
|
|
16
|
Velimogene aliplasmid.
|
Expert Opin Biol Ther
|
2010
|
0.78
|